| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael K Kießling, Jan P Nicolay, Tabea Schlör, Claus-Detlev Klemke, Dorothee Süss, Peter H Krammer, Karsten Gülo. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Oncotarget. vol 8. issue 28. 2018-04-11. PMID:28537899. |
ctcl cell lines and to a minor extent primary t cells from sézary patients without nras mutations are also affected by sorafenib-induced apoptosis suggesting a sensitizing role of nras mutations for sorafenib-induced apoptosis. |
2018-04-11 |
2023-08-13 |
Not clear |
| Craig E Eckfeldt, Emily J Pomeroy, Robin D W Lee, Katherine S Hazen, Lindsey A Lee, Branden S Moriarity, David A Largaespad. RALB provides critical survival signals downstream of Ras in acute myeloid leukemia. Oncotarget. vol 7. issue 40. 2018-02-23. PMID:27556501. |
whereas genetic disruption of nras(v12) expression in an nras(v12) and mll-af9-driven murine aml induced apoptosis of leukemic cells, inhibition of phosphatidylinositol-3-kinase (pi3k) and/or mitogen-activated protein kinase (mapk) signaling did not reproduce this effect. |
2018-02-23 |
2023-08-13 |
human |
| Sha Liu, Guozhen Gao, Dexiong Yan, Xiangjun Chen, Xingwei Yao, Shuzhong Guo, Guirong Li, Yu Zha. Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways. Cancer medicine. vol 6. issue 4. 2017-11-10. PMID:28332309. |
effects of mir-145-5p through nras on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting mapk and pi3k/akt pathways. |
2017-11-10 |
2023-08-13 |
mouse |
| Sha Liu, Guozhen Gao, Dexiong Yan, Xiangjun Chen, Xingwei Yao, Shuzhong Guo, Guirong Li, Yu Zha. Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways. Cancer medicine. vol 6. issue 4. 2017-11-10. PMID:28332309. |
after transfecting mir-145-5p mimics, mir-145-5p inhibitors, nras cdna and nras sirna into chl-1, vmm917 and sk-mel-28 cells, functional assays were used to detect the proliferation, apoptosis, invasion and migration, including mtt, flow cytometry, transwell and wound healing assays. |
2017-11-10 |
2023-08-13 |
mouse |
| Sha Liu, Guozhen Gao, Dexiong Yan, Xiangjun Chen, Xingwei Yao, Shuzhong Guo, Guirong Li, Yu Zha. Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways. Cancer medicine. vol 6. issue 4. 2017-11-10. PMID:28332309. |
through targeting nras, mir-145-5p could suppress cell proliferation, invasion, and migration and induce apoptosis of chl-1 and vmm917 melanoma cells by inhibiting mapk and pi3k/akt pathways. |
2017-11-10 |
2023-08-13 |
mouse |
| Michael K Kiessling, Alessandra Curioni-Fontecedro, Panagiotis Samaras, Silvia Lang, Michael Scharl, Adriano Aguzzi, Derek A Oldrige, John M Maris, Gerhard Rogle. Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PloS one. vol 11. issue 1. 2016-07-26. PMID:26821351. |
we found that everolimus alone induced apoptosis in nras mutant neuroblastoma. |
2016-07-26 |
2023-08-13 |
Not clear |
| Celia J Vogel, Marjon A Smit, Gianluca Maddalo, Patricia A Possik, Rolf W Sparidans, Sjoerd H van der Burg, Els M Verdegaal, Albert J R Heck, Ahmed A Samatar, Jos H Beijnen, A F Maarten Altelaar, Daniel S Peepe. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK. Pigment cell & melanoma research. vol 28. issue 3. 2016-01-05. PMID:25728708. |
cooperative induction of apoptosis in nras mutant melanoma by inhibition of mek and rock. |
2016-01-05 |
2023-08-13 |
Not clear |
| Julia Cisilotto, Misael Ferreira, Fabiola Branco Filippin-Monteiro, Adailton Joao Bortoluzzi, Marcus Mandolesi Sa, Tania Beatriz Creczynski-Pas. Isothiouronium salts reduce NRAS expression, induce apoptosis and decrease invasion of melanoma cells. Anti-cancer agents in medicinal chemistry. vol 15. issue 3. 2015-12-23. PMID:25469513. |
isothiouronium salts reduce nras expression, induce apoptosis and decrease invasion of melanoma cells. |
2015-12-23 |
2023-08-13 |
Not clear |
| Ha Linh Vu, Andrew E Apli. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma. Molecular cancer research : MCR. vol 12. issue 10. 2015-07-24. PMID:24962318. |
in three-dimensional systems that mimic the dermal microenvironment, tbk1 depletion or inhibition cooperated with mek inhibitors to promote apoptosis, particularly in the context of mek-insensitive mutant nras. |
2015-07-24 |
2023-08-13 |
Not clear |
| Asami Takashima, Brandon English, Zhihong Chen, Juxiang Cao, Rutao Cui, Robert M Williams, Douglas V Falle. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS chemical biology. vol 9. issue 4. 2015-07-01. PMID:24506253. |
inhibition of pkcδ, by sirna or small molecule inhibitors, suppressed the growth of multiple melanoma cell lines carrying nras mutations, mediated via caspase-dependent apoptosis. |
2015-07-01 |
2023-08-12 |
Not clear |
| Asami Takashima, Brandon English, Zhihong Chen, Juxiang Cao, Rutao Cui, Robert M Williams, Douglas V Falle. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS chemical biology. vol 9. issue 4. 2015-07-01. PMID:24506253. |
taken together, the present work demonstrates that inhibition of pkcδ by novel small molecule inhibitors causes caspase-dependent apoptosis mediated via the jnk-h2ax pathway in melanomas with nras mutations or braf inhibitor resistance. |
2015-07-01 |
2023-08-12 |
Not clear |
| Harish Potu, Luke F Peterson, Anupama Pal, Monique Verhaegen, Juxiang Cao, Moshe Talpaz, Nicholas J Donat. Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget. vol 5. issue 14. 2015-06-05. PMID:24980819. |
usp5 knockdown overcame acquired vemurafenib resistance and sensitized braf and nras mutant melanoma cells to apoptosis initiated by mek inhibitor, cytokines or dna-damaging agents. |
2015-06-05 |
2023-08-13 |
mouse |
| Michael R Burgess, Eugene Hwang, Ari J Firestone, Tannie Huang, Jin Xu, Johannes Zuber, Natacha Bohin, Tiffany Wen, Scott C Kogan, Kevin M Haigis, Deepak Sampath, Scott Lowe, Kevin Shannon, Qing L. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. vol 124. issue 26. 2015-02-23. PMID:25361812. |
treating recipient mice transplanted with primary nras(g12d) amls with 2 potent allosteric mitogen-activated protein kinase kinase (mek) inhibitors (pd0325901 or trametinib/glaxosmithkline 1120212) significantly prolonged survival and reduced proliferation but did not induce apoptosis, promote differentiation, or drive clonal evolution. |
2015-02-23 |
2023-08-13 |
mouse |
| Filip Janku, Ahmed O Kaseb, Apostolia M Tsimberidou, Robert A Wolff, Razelle Kurzroc. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. vol 5. issue 10. 2015-01-23. PMID:24931142. |
detected molecular aberrations led to putative activation of the pi3k/akt/mtor pathway (n=3 [mtor, pik3ca, nf1]), wnt pathway (n=6 [ctnna1, ctnnb1]), mapk pathway (n=2 [map2k1, nras]), and aberrant dna repair mechanisms, cell cycle control and apoptosis (n=18 [atm, atr, bap1, ccnd1, cdkn2a, cdk4, fgf3, fgf4, fgf19, mcl1, mdm2, rb1, tp53]). |
2015-01-23 |
2023-08-13 |
Not clear |
| Liting Xue, John A Pulikkan, Peter J M Valk, Lucio H Castill. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis. Blood. vol 124. issue 3. 2014-10-06. PMID:24894773. |
furthermore, nras(lsl-g12d); cbfb(56m) leukemic cells were sensitive to pharmacologic inhibition of the mek/erk signaling pathway, increasing apoptosis and bim protein levels. |
2014-10-06 |
2023-08-13 |
mouse |
| Stephanie Beurlet, Nader Omidvar, Petra Gorombei, Patricia Krief, Carole Le Pogam, Niclas Setterblad, Pierre de la Grange, Christophe Leboeuf, Anne Janin, Maria-Elena Noguera, Florence Hervatin, Laure Sarda-Mantel, Marina Konopleva, Michael Andreeff, Andrea W Tu, Alice C Fan, Dean W Felsher, Anthony Whetton, Marika Pla, Robert West, Pierre Fenaux, Christine Chomienne, Rose Ann Padu. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. vol 122. issue 16. 2013-12-12. PMID:23943652. |
treatment significantly extended lifespan, increased survival of lethally irradiated secondary recipients transplanted with cells from treated mice compared with cells from untreated mice, with a reduction of bm blasts, lin-/sca-1(+)/c-kit(+), and progenitor populations by increased apoptosis of infiltrating blasts of diseased mice assessed in vivo by technicium-labeled annexin v single photon emission computed tomography and ex vivo by annexin v/7-amino actinomycin d flow cytometry, terminal deoxynucleotidyltransferase-mediated dutp nick end labeling, caspase 3 cleavage, and re-localization of the nras:bcl-2 complex from mitochondria to plasma membrane. |
2013-12-12 |
2023-08-12 |
mouse |
| Fred M Kaplan, Curtis H Kugel, Neda Dadpey, Yongping Shao, Ethan V Abel, Andrew E Apli. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. The Journal of biological chemistry. vol 287. issue 50. 2013-02-12. PMID:23076151. |
expression of mutant nras in parental braf(v600) cells was sufficient to by-pass plx4720 effects on erk1/2 signaling, entry into s phase and susceptibility to apoptosis in a manner dependent on the raf binding site in nras. |
2013-02-12 |
2023-08-12 |
Not clear |
| Lawrence N Kwong, James C Costello, Huiyun Liu, Shan Jiang, Timothy L Helms, Aliete E Langsdorf, David Jakubosky, Giannicola Genovese, Florian L Muller, Joseph H Jeong, Ryan P Bender, Gerald C Chu, Keith T Flaherty, Jennifer A Wargo, James J Collins, Lynda Chi. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nature medicine. vol 18. issue 10. 2013-01-09. PMID:22983396. |
here, leveraging an inducible mouse model of nras-mutant melanoma, we show that pharmacological inhibition of mitogen-activated protein kinase kinase (mek) activates apoptosis but not cell-cycle arrest, which is in contrast to complete genetic neuroblastoma ras homolog (nras) extinction, which triggers both of these effects. |
2013-01-09 |
2023-08-12 |
mouse |
| Michael K Kiessling, Patrick A Oberholzer, Chandrani Mondal, Maria B Karpova, Marie C Zipser, William M Lin, Michael Girardi, Laura E Macconaill, Sarah M Kehoe, Charlie Hatton, Lars E French, Levi A Garraway, Gernot Polier, Dorothee Süss, Claus-Detlev Klemke, Peter H Krammer, Karsten Gülow, Reinhard Dumme. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood. vol 117. issue 8. 2011-05-12. PMID:21209378. |
knockdown of nras by sirna induced apoptosis in mutant hut78 cells but not in ctcl cell lines lacking ras mutations. |
2011-05-12 |
2023-08-12 |
Not clear |
| Juan R Lopez, Sandra M H Claessen, Merryn V E Macville, Jozefa C M Albrechts, Britt Skogseid, Ernst-Jan M Spee. Spectral karyotypic and comparative genomic analysis of the endocrine pancreatic tumor cell line BON-1. Neuroendocrinology. vol 91. issue 2. 2010-06-10. PMID:19887762. |
apart from deregulation of the cell cycle and p53 pathway this finding indicates escape from replicative senescence (induced by mutated nras) and detachment-induced apoptosis as molecular mechanisms underlying the tumorigenesis of bon-1 cells. |
2010-06-10 |
2023-08-12 |
human |